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Isocitrate dehydrogenase 2 (IDH2) is located in the mitochondrial matrix. IDH2 acts in the forward Krebs cycle as an
NADP+-consuming enzyme, providing NADPH for maintenance of the reduced glutathione and peroxiredoxin systems and
for self-maintenance by reactivation of cystine-inactivated IDH2 by glutaredoxin 2. In highly respiring cells, the resulting
NAD+ accumulation then induces sirtuin-3-mediated activating IDH2 deacetylation, thus increasing its protective function.
Reductive carboxylation of 2-oxoglutarate by IDH2 (in the reverse Krebs cycle direction), which consumes NADPH, may follow
glutaminolysis of glutamine to 2-oxoglutarate in cancer cells. When the reverse aconitase reaction and citrate eﬄux are added, this
overall “anoxic” glutaminolysis mode may help highly malignant tumors survive aglycemia during hypoxia. Intermittent glycolysis
would hypothetically be required to provide ATP. When oxidative phosphorylation is dormant, this mode causes substantial
oxidative stress. Arg172 mutants of human IDH2—frequently found with similar mutants of cytosolic IDH1 in grade 2 and 3
gliomas, secondary glioblastomas, and acute myeloid leukemia—catalyze reductive carboxylation of 2-oxoglutarate and reduction
to d-2-hydroxyglutarate, which strengthens the neoplastic phenotype by competitive inhibition of histone demethylation and
5-methylcytosine hydroxylation, leading to genome-wide histone and DNA methylation alternations. d-2-hydroxyglutarate also
interferes with proline hydroxylation and thus may stabilize hypoxia-induced factor α.
1. OxidativePhosphorylation and
GlutaminolysisinCancerCells
1.1. Strategies for Survival of Malignant Tumors. During ma-
lignant transformation, cells undergo stages of gene expres-
sion reprogramming and mutagenesis that alter their meta-
bolicphenotype(s)[1–5].Initialstimuli (notallknown)dys-
regulate information signaling and activate oncogenes and/
or cancer stem cells, resulting in a partial glycolytic “War-
burg” phenotype [1–5] in which pyruvate is diverted, at
least to a certain extent, from oxidative phosphorylation
(OXPHOS). High proliferation and impaired angiogenesis
subsequently cause hypoxia in certain regions within a grow-
ing tumor, and then hypoxia-mediated metabolic repro-
gramming (such as that promoted by hypoxia-induced fac-
tor, HIF [6–8]) further intensiﬁes the glycolytic phenotype
and may nearly completely divert pyruvate from pyruvate
dehydrogenase(PDH),thatis,fromOXPHOS.Thesustained
high rate of cell proliferation, however, results in aglycemia,
initiating the revival of OXPHOS in conjunction with the
promotion of glutaminolysis [1, 2, 9, 10]. The overall
glutaminolysis provides cytosolic pyruvate/lactate and also
yields NADPH via citrate export from mitochondria and
subsequent ATP-citrate lyase and malic enzyme reactions.
This compensates for the reduced net energy production
by the glycolytic pathway and pentose phosphate pathway
(PPP).Pyruvateimportedintomitochondriaistheprecursor
of not only acetyl-CoA but also citrate, which is required
for fatty acid synthesis and hence for phospholipid synthesis,
so it is essential for cell growth [1–5]. The ﬁnal established
phenotype is exempliﬁed by human glioblastoma cells,
which, despite their low respiration, maintain a constant2 International Journal of Cell Biology
pyruvate ﬂux through PDH and hence partial OXPHOS [9].
Oxaloacetate, however, may also be provided by the pyruvate
carboxylase reaction [11].
1.2. Glutaminolysis at Rejuvenated OXPHOS. For the pur-
pose of this paper, we shall use the term “glutaminolysis” in
a more general way than just the transformation of gluta-
mine to 2-oxoglutarate (2OG). We categorize glutaminolysis
according the fate of 2OG after its initial formation from
glutamine [1]. If 2OG resulting from glutamine acts in
the forward Krebs cycle (despite possible ongoing citrate
extrusion and truncation of the cycle so that aconitase and
“classic” NAD+-dependent isocitrate dehydrogenase (IDH3)
reactionsarenotrequired),wedeﬁnethesystemofmetabolic
reactions involved as “OXPHOS glutaminolysis.” This term
points out to its essential dependence on succinate dehydro-
genase(ComplexII)andhenceonrespirationandOXPHOS.
In contrast, when the reductive carboxylation of 2OG by
isocitrate dehydrogenase 2 (IDH2) (in the counter Krebs
cycle direction) consuming NADPH follows glutaminolysis
of glutamine to 2OG and when the reverseaconitase reaction
and citrate eﬄux are added, we deﬁne that system as “reduc-
tive carboxylation glutaminolysis” (RCG), also referred to as
“anoxic glutaminolysis.” The latter term denotes the absolute
independence of oxygen (respiration).
In general, glutaminolysis is an anaplerotic pathway of
the Krebs cycle. Although it acts frequently in broad cancer
types, glutaminolysis is not universal for all cancers [3–5]. In
cancer cells employing OXPHOS glutaminolysis, glutamine
can fully compensate for the lack of glucose in terms of
energy generation and syntheses of precursors for anabolic
pathways [3–5]. Thus, to survive under conditions of limited
glucose, highly glycolytic cancer cells may adapt to glu-
taminolysis, which in its OXPHOS mode restores OXPHOS
and may restore also at least partial PDH function [1, 3, 12–
14]. In normal cells, mitochondrial glutaminase catabolizes
glutamine to produce ammonia and glutamate, which is
furthertransaminatedbyglutamatedehydrogenaseinto2OG
to feed the Krebs cycle [15]. In malignant tumors, negative
allosteric eﬀectors, such as GTP, inhibit glutamate dehydro-
genase, resulting in a move toward glutaminolysis, where
glutamate and pyruvate are reactants in a transamination
reaction that produces, for example, alanine and 2OG by
alanine aminotransferase (transaminase) [15]. In cancer
cells, 2OG usually feeds the forward-running Krebs cycle
truncated after citrate synthase during citrate extrusion, so
that aconitase and “classic” NAD+-dependent IDH3 reac-
tions are not required [1, 5]. This OXPHOS glutaminolytic
mode is strictly dependent on oxaloacetate and acetyl-CoA,
that is, on the citrate synthase reaction; hence, it proceeds
only in cells in which oxaloacetate is provided by malate
dehydrogenase fed by the Krebs cycle as well as by malate
import from the cytosol, where malate originates from ATP-
citratelyasereaction.LikewiseincompleteinhibitionofPDH
restores acetyl-CoA in mitochondria (the pyruvate pool is
split between the PDH and transaminase reactions). An
alternative oxaloacetate source is provided by pyruvate car-
boxylase reaction [11].
Also, the mitochondrial malic enzyme may contribute to
this pool by producing pyruvate from malate [16]. Citrate is
extruded from mitochondria and converted to oxaloacetate
and acetyl-CoA by ATP citrate lyase [17]. Acetyl-CoA is
then used to produce fatty acids by fatty acid synthase and
cholesterol for general lipid synthesis, which is essential for
cancer cell proliferation [18, 19]. In glioblastoma, if there is
excess NADH in the cytoplasm (produced by aerobic glycol-
ysis), the cytosolic oxaloacetate is converted ﬁrst to malate by
malate dehydrogenase and then to pyruvate by the cytosolic
malicenzyme,thusmayalsocontributetolactateproduction
[9, 20]. The cytosolic malic enzyme also produces NADPH
as another factor required for lipid biosynthesis. Moreover,
alanine that is released by transaminase is used for cytosolic
amino acid transformations and protein synthesis [1, 4, 5].
1.3. Glutaminolysis Independent of OXPHOS. Hypothetical-
ly, malignant tumors may survive on intermittent OXPHOS-
independent RCG (also termed “anoxic” glutaminolysis) in
parallel with intermittent glycolytic periods [1, 2]. RCG
utilizes reductive carboxylation of 2OG by the reverse
reaction of mitochondrial IDH2 at the expense of NADPH,
followed by the reverse aconitase reaction and citrate eﬄux
from the matrix [1–3, 21–23]. NADPH is provided by the
malic enzyme converting malate to pyruvate and might also
be provided by the mitochondrial transhydrogenase [24].
The OXPHOS independence of this mode means that it may
proceed at any level of hypoxia and even at anoxia, thus
increasing malignancy [1, 3]. However, it does not produce
ATP so parallel glycolytic periods are required [1]. The
reductive carboxylation involves IDH2, which converts 2OG
to isocitrate, from which the reverse aconitase reaction
producescitrate,whichisagainexportedfromthemitochon-
drial matrix to the cytosol for fatty acid and lipid synthesis.
Note that acetyl-CoA, and hence the PDH reaction, is not
required in this mode.
2. Isocitrate Dehydrogenase Enzyme Isoforms
2.1.OverviewofIDHIsoforms. Alleukaryotgenomescontain
three IDH genes. IDH3 encodes a mitochondrial matrix
NAD+-dependent octameric IDH3 (4α2β2γ subunits [25])
that acts in the Krebs cycle. IDH3 is allosterically positively
regulated by Ca2+, ADP, and citrate and negatively regu-
lated by ATP, NADH, and NADPH. The two other IDH
genes, IDH1 and IDH2, encode cytosolic and mitochondrial
matrix NADP+-dependent (or NADPH-dependent) IDH1
and IDH2, respectively, which are structurally and genet-
ically unrelated to IDH3 [26]( Table 1). IDH3 irreversibly
decarboxylates isocitrate to yield 2OG while reducing NAD+
to NADH, whereas IDH1 and IDH2 catalyze reversible
reactions, either decarboxylating isocitrate to 2OG while
reducing NADP+ to NADPH or acting in the reductive
carboxylation reaction to convert 2OG to isocitrate while
oxidizing NADPH to NADP+.
Heterozygous mutations in IDH2 at Arg172 and at the
analogous residue Arg132 in IDH1 are frequently found
in grade 2 and 3 gliomas, secondary glioblastomas, andInternational Journal of Cell Biology 3
Table 1: Kinetics of IDH isoforms as compared to homodimeric mutant enzymes with clinically relevant mutations. Unless speciﬁed “re-
ductive”, forward reactions were measured. “n.d.”: not determined.
Enzyme Organism/tissue Mutation conditions
Km
isocitrate
(μM)
Kl,2 - o x o -
glutarate
(μM)
Km NADP+
(μM)
Vmax
(μmol·min−1·mg−1) Reference
IDH1
Human wt 65 1900 49 44000s−1 [96]
Human R132H 370 24 84 38s−1 [96]
Human R132H Reductive 2OG: 965 n.d NADPH:
0.44 1000s−1 [96]
Human wt 6.4 n.d. n.d. 14 [101]
Human R132H 1280 n.d. n.d. 0.8 [101]
Rat liver wt 120 n.d. 150 70 [102]
IDH2
Porcine wt 8.4 n.d. 5.6 43 [103]
Porcine wt 6 n.d. 5 40 [51]
Porcine R133Q 990 n.d. 11 21 [51]
Rat liver wt 70 n.d. 60 66 [102]
Rat heart wt 45 80 46 16 [104]
Rat heart wt Ischemic 17 250 46 38 [104]
IDH3 Human wt No ADP 2000 n.d. NAD+:6 0 2 6 [ 105]
Human wt +1 mM ADP 50 n.d. n.d. n.d. [105]
acute myeloid leukemia (AML [27]), but they occur less
frequently in primary glioblastomas and other cancers [28–
37]. No homozygous deletions of IDH1 and IDH2 have been
found, as has been observed for classic tumor suppressors.
Nevertheless, mutated IDH1 and IDH2 exhibit a neomor-
phic enzyme activity, reducing 2OG to d-2-hydroxyglutarate
while converting NADPH to NADP+[23, 29, 36, 38–40].
Interestingly, the d-2-hydroxyglutarate thus formed further
promotes neoplasia by competitive inhibition of histone
demethylation and 5-methyl-cytosine hydroxylation, leading
to genome-wide alternations in the methylation of histones
and DNA [40]. It has also been reported that glioblastoma
SF188 cells produce d-2-hydroxyglutarate, in spite of lacking
the above-described mutations [41].
M o r e o v e r ,I D H 2 ,l i k e∼20% of other mitochondrial
enzymes [42, 43], is acetylated at lysines, which inactivates
the enzymatic activity. In turn, deacetylation of IDH2 by the
mitochondrial matrix deacetylase sirtuin 3 (SIRT3) activates
the enzyme to produce more NADPH [44]. In nonmalignant
cells, the cytosolic IDH1 is involved in lipid metabolism and
glucose sensing. IDH2 was traditionally considered to be
involved in the regulation of OXPHOS and redox home-
ostasis [45] (see Section 4), and its involvement in reductive
carboxylationhasbeenrecognizedonlyrecently(Sections2.4
and 3).
2.2. Speciﬁc Enzymatic Properties of IDH2. NADP+-depend-
ent oxidative decarboxylation of isocitrate to 2OG, as the
major function of IDH2 in nonmalignant cells, contributes
substantially to the control of mitochondrial redox balance
and the prevention of oxidative damage [45, 46]. Because
the IDH2 reaction is reversible, it may act in a “reverse”
Krebs cycle mode in the reductive carboxylation reaction
(see Section 2.4). IDH2 contains an N-terminal mitochon-
drial addressing sequence and hence is imported to the
mitochondrial matrix [45], although localization to nuclei
has also been reported [47]. The IDH2 l o c u si sa d j a c e n tt o
the gene for the α subunit of IDH3 [48]. IDH2 expression in
heart, skeletal muscle, and lymphocytes is quite substantial;
lower levels are found in liver, kidney, and lung [45, 47].
IDH2hasalsobeenfoundinculturedratneurons,astrocytes,
oligodendrocytes, and microglia [49]. Unlike IDH1, the 94-
kDa IDH2 (EC 1.1.1.42) is a homodimeric enzyme of two
413-amino acid subunits, each 47kDa [50, 51]( Figure 1).
IDH2 function requires a divalent metal ion, and bound
Mn2+ yields the maximum activity [52]. The structure of
the Mn2+-isocitrate binding site was mapped from the solved
crystal structure of porcine IDH2 [50]. Within the site,
Thr78, Ser95, and Asn97 (of the porcine sequence) donate
a hydrogen bond to the C3 carboxyl, whereas Asp252 and
Asp275 coordinate Mn2+. An additional six Arg residues
providehydrogenbondswithisocitrateoxygens[50].Hydro-
gen bonding of Lys212 with other residues between the two
subunits was also noted. The NADP+ binding site was origi-
nally predicted from the E. coli IDH structures, positioning
the 2-hydroxyl-bound phosphate to interact with His315
and Lys374 of porcine IDH2 [50]. Porcine Arg83 enhances
NADP+ aﬃnity by hydrogen bonding with the 3 -OH of
the nicotinamide ribose, and Asn328 provides a hydrogen
bond to the N1 of adenine [53]. For eﬃcient coenzyme
site function, a hydroxyl group must be present at position
373 (Thr373 of the porcine sequence), whereas Asp375 and
Lys260 contribute to coenzyme aﬃnity and catalysis [54, 55].
Within the numbering of the human IDH2 sequence,
mutations in Arg172 (an analog of frequently mutated
Arg132 of cytosolic IDH1 [56] )a r ed e t e c t e di ng l i o m a s
[23, 36, 37], and mutations in Arg172 and Arg140 (which4 International Journal of Cell Biology
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Figure 1: Main domains of the mitochondrial isocitrate dehy-
drogenase, IDH2.The homodimeric IDH2 of two 413-amino acid
subunits; each 47 kDa subunit is schematically illustrated according
the solved crystal structure of porcine IDH2 [50]. Residues 142–187
make up two stacked four-stranded antiparallel β-sheets (middle
whitemarble-shadeddomain).Mn2+ andisocitrateintheactivesite
are depicted as a blue circle and rod, respectively. Six Arg residues,
which provide hydrogen bonds with isocitrate oxygens [50], are not
depicted. Arg 83 (R83) interacts by hydrogen bonding with the 3 -
OH of the nicotinamide ribose and thus enhances NADP+ aﬃnity
[53]. An Arg residue corresponding to human Arg172, which is
often mutated in gliomas and AML, is indicated by an asterisk (∗).
For activity, the glutathionylation of Cys269 [46]( G S – S )m u s tb e
removed(X)byreactivationaidedbyglutaredoxin-2inthepresence
of reduced glutathionine, and the protein must be deacetylated by
SIRT3 [44]. We hypothesize that Lys212, Lys374, and Lys260 (in
porcine notation) are the prime candidates for acetylation causing
IDH2 inactivation.
is adjacent in the active site to Arg172 [50]) are found
in AML [57]. Mutations are apparent after the transition
from a normal cell to a clinically evident tumor. Arg172 (as
well as Arg132 of IDH1) provides hydrogen bonds to the
α and β carboxyls of isocitrate and may be important in
the transition from an open to closed state of the active site
[50]. The porcine Arg residue mutated to Asn in a position
analogous to human Arg172 displays a twofold reduction in
speciﬁc activity and a Km for isocitrate that is two orders
of magnitude higher [51]( Table 1). Likewise, in lysates of
cells overexpressing IDH2, activity is reduced when Arg172
is substituted with Gly, Lys, or Met [37]. Nevertheless,
the existence of exclusively heterozygous IDH2 (and IDH1)
mutations in gliomas and AML and the small possibility
of dominant-negative mutations (minor mutant fractions
existing could not exert this role [39]) have led to the search
for other consequences of IDH1 and IDH2 mutations.
Arg132 mutants of cytosolic IDH1 [27]( Table 1)a n d
Arg172 mutants of mitochondrial IDH2 [23, 36, 38, 39]
possess the ability to reduce 2OG to d-2-hydroxyglutarate
while converting NADPH to NADP+. This is because the
active closed state of the enzyme exhibits a higher aﬃnity
for NADPH. Mutant IDH2 and IDH1 [27] are not supposed
to allow the reductive carboxylation reaction of 2OG to
isocitrate. However, consequences of these mutations have
appeared more detrimental than expected. Initially, the
production of d-2-hydroxyglutarate in gliomas, secondary
glioblastomas, and AML by mutant IDH2 results in a
decrease of 2OG and hence depletion of succinate, fumarate,
and malate from the rest of the Krebs cycle [23, 36, 39].
Interestingly,IDH2mutationsalsoleadtoincreasesinamino
acid levels [35] as would be expected for ongoing glu-
taminolysis.However,themostprofoundconsequencesstem
from the interference with epigenomics. Thus, the formed
d-2-hydroxyglutarate strengthens the neoplastic phenotype
by competitive inhibition of histone demethylation and
5-methyl-cytosine hydroxylation, leading to genome-wide
alternations in histone and DNA methylation [40]. More-
over, prolyl hydroxylase domain enzymes, which employ
2OG as a cofactor for marking hypoxia-induced factor-1α
(HIF1α) by proline hydroxylation, are inhibited by d-2-
hydroxyglutarate as well as by the lack of 2OG. As a result,
HIF1α is stabilized (if its inhibitor, aspartyl hydroxylase
factor inhibiting HIF, is not active) even at normoxia and
thus can elicit the otherwise hypoxic reprogramming of gene
expression [58].
2.3. Regulation of IDH2 Activity. Glutathionylation of pro-
teins by the reversible glutaredoxin (thioltransferase) reac-
tion serves to protect against irreversible oxidation of cys-
teines[59].SuchprotectionhasbeendemonstratedforIDH2
in that oxidized glutathione can inactivate IDH2 by forming
a mixed disulﬁde bond with Cys269 [46]. The inactivated
IDH2 is reactivated by glutaredoxin 2 in the presence of
reduced glutathione. Also, IDH2 in mouse heart may exist
in complex with calcineurin, containing as well aconitase,
malate dehydrogenase, and MnSOD [55].
Another important level of regulation of IDH2 activity
is provided by mitochondrial SIRT3. Posttranslational mod-
iﬁcations of numerous mitochondrial proteins frequently
occur via acetylation/deacetylation of lysine residues [42, 43,
60,61].Among sevensirtuinfamilymembers,SIRT3,SIRT4,
andSIRT5areenrichedinmitochondria,suchasexempliﬁed
and well described for SIRT3 up to date [42, 43, 62]. It has
been reported that incubation of SIRT3 with IDH2 increases
the dehydrogenase activity [62]. Recently, caloric restriction
was demonstrated to act via IDH2 deacetylation through
SIRT3 [44]. Caloric restriction prevents age-related hearing
loss by reducing oxidative DNA damage, but such is not the
case for mice lacking SIRT3 [44]. SIRT3 directly deacetylates
the IDH2 lysines and thus activates IDH2, which in its
forward mode could result in increased NADPH levels and
thereby maintain reduced glutathione levels in mitochon-
dria. Indeed, overexpression of SIRT3 and/or IDH2 leads to
increased NADPH levels and is protective against oxidative
stress-induced cell death [44]. Lys212, Lys374, and Lys260
(porcine sequence) may be the prime candidates for acety-
lation/inactivation. It remains to be shown that SIRT3 can
deacetylate these residues, however, and it should be investi-
gated which reaction modes are active and possible before
and after such activation, speciﬁcally, whether the reverse,
NADPH-dependent, reaction and RCG could be activated.
2.4. Reductive Carboxylation Reaction. As predicted in 1994
by Sazanov and Jackson [63] (see also [64]), the reductive
carboxylation reaction by native IDH2 converts 2OG to
isocitrate while oxidizing NADPH to NADP+. The Arg172International Journal of Cell Biology 5
and Arg140 mutants of IDH2 [23, 36, 38, 39] and glioblas-
toma SF188 cells under hypoxia [41]c o n v e r t2 O Gt od-
2-hydroxy-glutarate in this “reverse-reaction” mode. This
reductive carboxylation would proceed better in vivo when
followed by the reverse aconitase reaction and subsequent
citrate export from the mitochondrial matrix. Reductive
carboxylation was demonstrated for IDH2 in 2002 [65]
and was indicated for cancer cells in transformed brown
adipocytes [22], pediatric glioma SF188 cells [23, 41], and
UOK262 cells (derived from a renal tumor in a patient
with hereditary leiomyomatosis, these cells are defective in
respiration and devoid of fumarate hydratase activity) [2].
Reductive carboxylation accompanied by citrate eﬄux has
also been found in quiescent ﬁbroblasts and is enhanced in
contact-inhibited ﬁbroblasts [66]. IDH2 silencing in SF188
cells results in diminished conversion of glutamine to citrate
[23, 41]. Recently, reductive carboxylation was detected in
human osteosarcoma 143B cells in which the mitochondrial
DNA encoded a loss-of-function mutation in respiratory
chain Complex III (CYTB 143B cells) [2]. Because only low-
level reductive carboxylation was detected in wild-type 143B
cells,theauthorssuggestedthattheimpairmentofOXPHOS,
such as given by mutant mitochondrial DNA, induces RCG.
Silencing of either IDH1 or IDH2 reduces the growth of both
wild-typeandCYTB143Bcells[2].Moreover,unlikeinwild-
type 143B cells, de novo fatty acid synthesis from glutamine
as a precursor is prevalent in CYTB 143B cells [2]. Reductive
carboxylation in fumarate hydratase—devoid UOK262 cells,
which are defective in respiration, has also been identiﬁed
in parallel with OXPHOS glutaminolysis [2]. Interestingly,
inhibition of respiration in mouse embryonic ﬁbroblasts
via administration of antimycin, rotenone, or metformin
induces a switch towards RCG [2]. Thus, these data provide
additional support for the authors’ hypothesis that RCG
is a common cellular response to impaired mitochondrial
metabolism [2].
3. ContributionofIDH2toGlutaminolysisThat
Is Independent of OXPHOS
3.1. Evidence for Reverse Reactions in the Krebs Cycle. The
reverse IDH2 reaction was also considered such that IDH2
acts together with the forward reaction of IDH3 in a dissipa-
tiveisocitrate/2OGcycle[63](seeSection 4.2).Thereductive
carboxylation reaction and the overall RCG may indeed
proceed together with the forward decarboxylation reaction
[2, 22]. The best evidence was obtained by tracking the
metabolitesof 13C-labeledglutamine,suchastheappearance
of 13C-label in citrate [2, 22, 23, 41].
3.2. RCG in Cancer Cells. The ﬁrst demonstrations of RCG
in cancer cells [22, 23, 41] are consistent with the recent
ﬁndingsthatmutantIDH2ingliomasandAMLalsoproduce
d-2-hydroxyglutarate from 2OG by “alternate” reduction.
Because these mutants are heterozygous, both RCG and
the production of d-2-hydroxyglutarate might occur. The
former reaction involves the nonmutant NADPH-dependent
IDH2 “reverse” reaction followed by isocitrate conversion
to citrate and by citrate export. The mutant IDH2 (but
maybe also wild-type IDH2, see [41]) acting in a “reverse”
mode also produces d-2-hydroxyglutarate, which cannot
be transformed by aconitase; however, it further enhances
the malignant phenotype [40]. The importance of this
neomorphic IDH2 activity for the cancer phenotype is
valid even without consideration of d-2-hydroxyglutarate
interference with epigenetics and the HIF pathway, because
IDH2 depletes 2OG from the Krebs cycle.
The consumption of NADPH in the matrix is a con-
sequence of the altered homeostasis of reactive oxygen
species (ROS) in cancer cells (see Section 4.2) and is also
possible due to NADPH production by the mitochon-
drial malic enzyme [1, 5] and transhydrogenase [24, 63,
67]. It is not known whether SIRT3-based activation also
aﬀects this reverse (NADPH-dependent) IDH2 reaction.
Although NADH, rather than NAD+, accumulates in the
mitochondrial matrix of highly glycolytic cancer cells in
which OXPHOS is dormant (Figure 2(a)), NAD+ might
be produced by the inner membrane H+ transhydrogenase
from NADH with the simultaneous formation of NADPH
from NADP+ in the matrix [67], thereby activating SIRT3-
mediated IDH2 deacetylation. Moreover, the usual acetyla-
tion of proteins may be retarded in highly glycolytic cancer
cells; hence, no SIRT3-mediated deacetylation would be
required.
3.3. Intermittent Nature of RCG. Unlike glycolysis, RCG does
not form ATP. Hence, either RCG coexistence with glycolysis
or intermittent glycolysis is expected under hypoxic and
deep hypoxic conditions [1]; that is, RCG may help cancer
cells survive aglycemia and hypoxia in malignant cells [68].
Nevertheless, before all ATP stores become consumed, gly-
colysis must be reestablished. If this happens, it may help the
tumor cell survive even in anoxia. As clearly demonstrated
by the examples of gliomas and AML with the oncogenic
metabolite d-2-hydroxyglutarate, the establishment of RCG,
even concomitantly with OXPHOS glutaminolysis (note that
this mode does not require IDH2 and aconitase reactions),
helps to accelerate the malignant phenotype. Recently, it
has been demonstrated that hypoxia elevates RCG in SF188
cells in a HIF-dependent manner [41]. SF188 cells were able
to proliferate at 0.5% O2 even if such hypoxic conditions
substantially diminished glucose-dependent production of
citrate, that is, OXPHOS and forward Krebs cycle participa-
tion [41].
4. Role of IDH2inROS Homeostasis
4.1. Regulation of ROS Homeostasis in Nonmalignant Cells.
A major function of IDH2 in nonmalignant cells, when
acting within the forward Krebs cycle, is likely maintaining
an adequate pool of reduced glutathione and peroxiredoxin
by providing NADPH. This function improves the mito-
chondrial redox balance and prevents oxidative damage [45,
46,69],includingheat-shock-inducedoxidativedamage[70]
and numerous consequent events of oxidative stress, such as6 International Journal of Cell Biology
ROS-induced apoptosis [71, 72], apoptosis induced by ion-
izing radiation [73] and cadmium [74], and staurosporine-
induced cell death [75]. The lack of IDH2 or its activity ele-
vates cytosolic ROS, lipid peroxidation, and oxidative DNA
damageandshortenscellsurvivalafteroxidantexposure[69,
71–73]. Also, susceptibility to curcumin-induced apoptosis
has been demonstrated upon IDH2 silencing in HCT116
cells [76]. Cardiac hypertrophy development is attributed to
a decrease in IDH2 activity owing to the lipoperoxidation
product 4-hydroxynonenal and oxidative stress [77]. IDH2 is
also protective for paraquat-mediated oxidative inactivation
of aconitase in heart mitochondria [78]. Inactivation of
IDH2 activity by various ROS insults [79]i sa ni m p o r t a n t
factor that has to be accounted for in any consideration
of oxidative stress in cells. The forward Krebs cycle activity
of IDH2 is inactivated by 4-hydroxynonenal [80], singlet
oxygen [81], hypochlorous acid [82], aluminum [83], nitric
oxide [84], and peroxynitrite [85]. Peroxynitrite forms S-
nitrosothiol adducts on Cys305 and Cys387 of IDH2 under
nitrosative stress, such as that established in the liver of
ethanol-fed rats [85]. Glycation-mediated IDH2 damage has
also been reported [86].
IDH2 activity ﬁrst increases and then decreases with age
in ﬁbroblasts and liver, kidney, and testes tissues of rats
fed ad libitum but not of those fed a calorie-restricted diet
[87]. Recently, caloric restriction has been proven to act via
IDH2 deacetylation through SIRT3 and thus promote an
antioxidant role for IDH2-produced NADPH [44]. Again,
the activity within the forward Krebs cycle was considered.
It is not known whether SIRT3-mediated deacetylation also
activates the NADPH-dependent “reverse” reaction, that is,
reductive carboxylation.
4.2. The Dissipative Isocitrate/2OG Cycle. The dissipative
isocitrate/2OG cycle has been suggested based on the
reductive carboxylation reaction of IDH2 (counter Krebs
cycle reaction direction, NADPH dependent) in conjunction
with the forward IDH3 reaction in the canonical Krebs
cycle [63]. The cycle may manifests itself in the absence
of citrate export from mitochondria, as normally occurs
in non-malignant cells, since cycling is impossible when
reversed aconitase reaction depletes isocitrate. The cycle
would also be possible at suﬃcient reactant pools and inner
membrane energization. Isocitrate formed by the reductive
carboxylation reaction of IDH2 is processed back to 2OG by
IDH3. Although in non-malignant cells Complex I regener-
ates NADH to NAD+ and NADP+ could be regenerated to
NADPH by, for example, mitochondrial malic enzyme, with
increasing malignancy (more dormant state of mitochon-
dria and hence decreasing respiration), the mitochondrial
inner membrane H+ transhydrogenase [24, 63, 67]m a y
alternatively transfer electrons from NADH and NADP+ to
NAD+and NADPH at the expense of the proton-motive
force [24]. However, it remains to be determined, whether
this cycle is possible with d-2-hydroxyglutarate. If d-2-
hydroxyglutarate was metabolized by IDH3 in the canonical
Krebs cycle, then the cycle would be automatically induced
bytheappearanceof d-2-hydroxyglutarateatsimultaneously
active H+ transhydrogenase. Nevertheless OXPHOS cannot
be completely dormant, since proton-motive force would
be required for this normal “forward” transhydrogenase
reaction [24].
4.3. Consequences of Reductive Carboxylation for ROS Home-
ostasis in Cancer Cells. Consider the situation in highly
malignant cells in which energy is derived primarily from
glycolysis disconnected from OXPHOS (Warburg pheno-
type) and high reductive carboxylation glutaminolysis takes
place (Figure 2(a)). Presumably, OXPHOS impairment [2]
or deep hypoxia [41] may set up this metabolic pattern. In
this case, higher glucose-6-phosphate dehydrogenase activity
(the ﬁrst PPP enzyme) produces more NADPH [88]. It
may be erroneously considered as antioxidant action; how-
ever, because the constitutively expressed NADPH oxidase
isoform-4, NOX4 [89, 90], can consume a major portion
of the excess NADPH and produce more superoxide and
consequently release more H2O2 into the cytosol, the overall
reaction scheme may be prooxidant (Figure 2(a)). This
contributes to a much higher oxidative stress state in highly
malignant cancer cells. Recently, NOX4 was also suggested
to have mitochondrial localization [91]. Probably, NOX4 has
Km in the same order of magnitude as IDH enzymes. The
NOX4 consumption of NADPH leaves fewer redox equiva-
lentsforthereductionofcellularglutathioneandotherredox
systems [92–94]. The cytosolic oxidative stress is further
intensiﬁed by the slow electron transport in low respiring
(dormant)mitochondriaofhighlymalignantcancercells[1–
5, 68], resulting in more superoxide release to the cytosol as
well as the mitochondrial matrix from the respiratory chain.
The ongoing maximum reductive carboxylation reaction
further contributes to the oxidative stress by consuming
NADPH, thus leaving less NADPH for maintenance of the
reduced glutathione pool. Moreover, as mentioned above,
the accumulated NADH at slow respiration may lead to
NAD+ formation in the reversed H+ transhydrogenase
reaction by concomitant NADPH formation from NADP+
to further feed the NADPH pool and hence reductive
carboxylation. Simultaneously, NAD+ may lead to SIRT3-
mediated activation of IDH2, at least of its “forward mode”
[44], but it is not known whether reductive carboxylation is
also activated by deacetylation of IDH2.
4.4. Consequences of IDH2 Reaction within the Forward
Krebs Cycle for ROS Homeostasis in Cancer Cells. We next
consider an intermediate Warburg phenotype, characterized
by the mixed use of sole glycolysis, that is, aerobic glycolysis
producing lactate, and OXPHOS (Figure 2(b)). The latter
may be represented either by OXPHOS pyruvate metabolism
and/or by OXPHOS glutaminolysis. Under these conditions,
considerable cytosolic oxidative stress is expected because of
the elevated NOX4 activity, as described above. However, a
lower mitochondrial contribution to the cytosolic oxidative
stress exists owing to an intermediate level of respiration and
hence lower superoxide release from mitochondria to both
the cytosolic and matrix compartments [92]. There is also
lower oxidative stress expected in the matrix owing to theInternational Journal of Cell Biology 7
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Figure 2: Consequences of IDH2 functions for redox homeostasis in cancer cells and nonmalignant cells.
possible ongoing dissipative isocitrate/2OG cycle, which by
decreasingtheproton-motiveforce[63]decreasesmitochon-
drial superoxide formation [95]. This can be considered,
however, only when citrate eﬄux from mitochondria is not
dominant or when d-2-hydroxyglutarate would be cycling
instead of isocitrate/2OG. If this is the case, NAD+ rather
than NADH would accumulate, further feeding the isoci-
trate/2OG cycle by simultaneous action of the forward IDH3
reaction and reverse (reductive carboxylation) reaction of
IDH2. The accumulated NAD+ would also promote SIRT3-
mediated IDH2 deacetylation, consequently accelerating the
IDH2 branch of the reaction cycle (Figure 2(b)). Conditions
similar to those described here may occur at hypoxia.
4.5. Regulation of ROS Homeostasis in Nonmalignant Cells:
IDH2 Contribution. Finally, we consider the situation in
non-malignant cells, in which OXPHOS predominates and
the sole glycolysis and PPP activities are low (Figure 2(c)). In
this case, low oxidative stress in the cytosol is a consequence
of the negligible NOX4 activity and the low contribution of
mitochondria tothe cytosolic ROS pool. Underthese normal8 International Journal of Cell Biology
conditions, we assume that the forward IDH2 reaction
generates NADPH, which further improves the reduced state
of the mitochondrial matrix glutathione and peroxiredoxin
systems. Indeed, ample evidence suggests that in cells with
unattenuated OXPHOS, IDH2 plays an important antiox-
idant role that is further strengthened by NAD+ accumu-
lation in highly respiring cells. NAD+ then induces SIRT3-
mediated IDH2 deacetylation, thus increasing its protective
function in NADPH formation for the maintenance of the
reduced glutathione and peroxiredoxin systems and for self-
maintenance by the reactivation of cystine-inactivated IDH2
by glutaredoxin-2 [59].
4.6. IDH2-Dependent ROS Homeostasis at Glance. (a) Situa-
tion in cancer cells with a prevalent Warburg phenotype and
high reductive carboxylation. In the cytosol, higher glucose-
6-phosphate dehydrogenase activity (G6PDH) produces
higher NADPH within the pentose phosphate pathway
(PPP). NADPH-oxidase isoform-4 (NOX4) thus produces
more superoxide and consequently contributes to high levels
of reactive oxygen species (ROS) in the cytosol. The cytosolic
oxidative stress is further intensiﬁed by the slow electron
transport in low-respiring (dormant) mitochondria, leading
to higher superoxide release to the cytosol and matrix com-
partments. The ongoing maximum reductive carboxylation
reaction further contributes to oxidative stress by consuming
NADPH, thus leaving less for maintenance of the reduced
glutathione pool. The accumulated NADH at slow respi-
ration may lead to NAD+ f o r m a t i o ni nt h er e v e r s eH +
transhydrogenase (TH) reaction (due to low proton/motive
force) with concomitant NADPH formation from NADP+
to further feed the NADPH pool and hence reductive
carboxylation. Hypothetically, NAD+ may lead to sirtuin 3
(SIRT3)-mediated deacetylation/activation (+)of IDH2, but
it is not known whether reductive carboxylation is also
activated by deacetylation of IDH2. (b) Situation in cancer
cells with an intermediate Warburg phenotype and possible
OXPHOS glutaminolysis. The major contribution to the
cytosolic oxidative stress is the same as described above.
However, a lower mitochondrial contribution to cytosolic
ROS leads to intermediate oxidative stress under these con-
ditions. Indeed, an intermediate or high respiration leads
to much lower superoxide production and release from
the mitochondria to both the cytosolic and matrix com-
partments (dashed arrows). Lower oxidative stress is also
expected in the matrix owing to the ongoing dissipative
isocitrate/2OG cycle, which decreases further mitochon-
drial superoxide formation by decreasing the proton-motive
force. OXPHOS glutaminolysis may predominate under
these conditions; hence, RCG might not be completed and
the isocitrate/2OG cycle with forward H+ transhydrogenase
reaction may be initiated. NAD+ would accumulate owing
to high respiration, further feeding the isocitrate/2OG
cycle. The accumulated NAD+ would also promote SIRT3-
mediated deacetylation/activation of IDH2. (c) Situation in
nonmalignant cells. Aerobic glycolysis and PPP activity are
low; consequently, low oxidative stress in the cytosol also
results from the negligible NOX4 activity and the low
contribution of mitochondria to the cytosolic ROS. The
forward IDH2 reaction thus forms NADPH, which further
improves the reduced state in the mitochondrial matrix
glutathione and peroxiredoxin systems. As in (b), the NAD+
accumulation in highly respiring cells then induces SIRT3-
mediated deacetylation/activation of IDH2.
5. HypotheticalIDH2Involvementin
Redox Signaling
As brieﬂy described above, mutant IDH2 as well as IDH1
[96–100]p r o d u c ed-2-hydroxy-glutarate, which can initiate
an HIF-mediated “hypoxic type” of gene reprogramming
even at normoxia [58]. Nevertheless, detail investigations of
d-2-hydroxyglutarate eﬀects on HIF signaling are required,
since recently an opposite eﬀect, diminishing HIF levels by
inhibition of EGLN prolyl 4-hydroxylases, has been reported
[99]. Also, non-mutated IDH2 acting in the 2OG/isocitrate
cycle together with H+ transhydrogenase [63]c o u l dc o n -
tribute to the modulation of the ROS pool by initiating
an impulse originating from Complex III to dissipate the
proton-motive force, which reduces superoxide formation
in the mitochondrial respiratory chain [95]. In contrast to
mutantIDH2activity,theongoingdissipative2OG/isocitrate
cycle in the absence of citrate eﬄux from mitochondria
would retard HIF signaling.
6.FuturePerspectives
The discovery of mutant IDH2 and IDH1 in certain gliomas
and AML and their production of the oncogenic metabolite
d-2-hydroxyglutarate have unraveled a fascinating story of
cancer self-acceleration via intermittent episodes of genome
instability and metabolic remodeling and namely via epige-
nomic alterations [98, 100]. However, there are additional
aspects to be clariﬁed. First, the exact role of d-2-hydroxy-
glutarate must be further investigated to determine whether
itpromotesthereversecarboxylationmodeofglutaminolysis
and whether it acts in the dissipative 2OG/isocitrate cycle,
which would then become the 2OG/d-2-hydroxyglutarate
cycle, as we can now only speculate. Also, conditions under
whichd-2-hydroxyglutaratemightbeformedinnon-mutant
IDH2 should be deﬁned. Second, the role of SIRT3 has
to be established to determine whether it prevents or
accelerates malignancy via IDH2. In particular, the question
whether SIRT3 activates reductive carboxylation must be
resolved. Finally, the role of IDH2 in other cancer types
distinct from AML, gliomas, and renal tumors of hereditary
leiomyomatosis should be investigated.
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